drugset / Trial / NCT02241395

Cell Therapy as Treatment for Cerebral Palsy

NCT02241395

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.

Timeline

Start
2013-08
Primary completion
2018-06
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous bone marrow mononuclear cells Cell therapy Intrathecal

Indications